Publication date: Mar 21, 2025 The treatment of mycobacteriosis depends on the species causing the disease and its susceptibility to drugs. Clarithromycin represents the cornerstone of regimens for fast-growing non-tuberculous ... Read more

Publication date: Mar 20, 2025 The increasing prevalence of antibiotic resistance, the stagnation of antibiotic development, and the adaptive capacity of bacteria to subvert the host immune response combine to ... Read more

Publication date: Mar 21, 2025 Mycobacterial type II NADH dehydrogenase (NDH-2) is a promising drug target because of its central role in energy metabolism in Mycobacterium tuberculosis and other pathogens, ... Read more

Publication date: Mar 01, 2025 Tuberculosis is a global public health threat as an infectious disease, and effective blocking of transmission relies on timely diagnosis. Although a number of laboratory ... Read more

Publication date: Mar 17, 2025 While most people contain Mycobacterium tuberculosis infection, some individuals develop active disease, usually within two years of infection. Why immunity fails after initially controlling infection ... Read more

Publication date: Mar 17, 2025 Non-tuberculous mycobacteria (NTM) are widespread and found in all biotopes, including caves. Some NTMs are potentially pathogenic, causing serious diseases (mycobacterioses) in both animals and ... Read more

Publication date: Mar 17, 2025 Approximately one-quarter of the global population is estimated to be infected with Mycobacterium tuberculosis. New developments in vaccine design and therapeutics are urgently needed, particularly ... Read more

Publication date: Mar 17, 2025 Approximately one-quarter of the global population is estimated to be infected with Mycobacterium tuberculosis. New developments in vaccine design and therapeutics are urgently needed, particularly ... Read more